Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
A phase III trial of semaglutide achieved 63% resolution of MASH without worsening fibrosis
10.1016/j.cell.2006.06.025 410 Wasilewski M., Semenzato M., Rafelski S
Journal of Physiology, 589(Pt 4), 963973
Fazekas T et al
Our approach is intentional and conservative, using peptides to support long-term health rather than chasing short-term results
Retatrutide won't be available until at least early 2026 as it's still in phase-3 clinical trials
US$ 27.73
US$ 23.02
US$ 27.46
US$ 26.58
US$ 20.21
US$ 24.74
US$ 23.53
US$ 20.37
